Sino Biopharmaceutical's Tulobuterol Patch Gains NMPA Approval
CompanyDrug

Sino Biopharmaceutical’s Tulobuterol Patch Gains NMPA Approval

Regeneron's Q4 Financials Show 10% Revenue Growth, Driven by Eylea and Libtayo
Company

Regeneron’s Q4 Financials Show 10% Revenue Growth, Driven by Eylea and Libtayo

AstraZeneca's 2024 Financials Beat Expectations with 21% Revenue Growth
Company

AstraZeneca’s 2024 Financials Beat Expectations with 21% Revenue Growth

Eli Lilly's Q4 Sales Soar 45% to $13.53B on Strength of GLP-1 Drugs
Company

Eli Lilly’s Q4 Sales Soar 45% to $13.53B on Strength of GLP-1 Drugs

GSK Reports 7% Full-Year Sales Growth in 2024, Driven by Specialty Medicines
Company

GSK Reports 7% Full-Year Sales Growth in 2024, Driven by Specialty Medicines

MSD Reports Strong Global Sales Growth in 2024, Despite China Challenges
Company

MSD Reports Strong Global Sales Growth in 2024, Despite China Challenges

Amgen Reports Strong Q4 and Full-Year 2024 Sales Growth
Company

Amgen Reports Strong Q4 and Full-Year 2024 Sales Growth

Novo Nordisk Reports Soaring Global Sales in 2024, Driven by Diabetes and Obesity Care
Company

Novo Nordisk Reports Soaring Global Sales in 2024, Driven by Diabetes and Obesity Care

Astellas Pharma Submits NDA for Avacincaptad Pegol in Japan for Geographic Atrophy
CompanyDrug

Astellas Pharma Submits NDA for Avacincaptad Pegol in Japan for Geographic Atrophy

Roche's Susvimo Approved by FDA for Diabetic Macular Edema
CompanyDrug

Roche’s Susvimo Approved by FDA for Diabetic Macular Edema

FDA Approves Enhertu for HER2-Low and HER2-UltraLow Breast Cancer
CompanyDrug

FDA Approves Enhertu for HER2-Low and HER2-UltraLow Breast Cancer

Immunophage Partners with GoBroad Cancer Hospital for IPG1094 Phase II Study
CompanyDeals

Immunophage Partners with GoBroad Cancer Hospital for IPG1094 Phase II Study